Chemotherapy with atezolizumab for small cell or neuroendocrine carcinoma of the prostate: A single institution experience.

Christopher E WeeBrian A CostelloJacob J OrmeJ Fernando QuevedoLance C Pagliaro

Published in: The Prostate (2021)

Small cell or neuroendocrine carcinoma of the prostate was associated with poor survival outcomes despite adding immunotherapy (atezolizumab) to chemotherapy (carboplatin and etoposide). To our knowledge, there has been no demonstrable benefit of adding immunotherapy to chemotherapy in this setting.

Keyphrases

prostate cancer
locally advanced
single cell
cell therapy
benign prostatic hyperplasia
randomized controlled trial
squamous cell carcinoma
radiation therapy
bone marrow
open label